.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XF03_Bexarotene.Bexarotene .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XF03_Bexarotene.Bexarotene| name: | Bexarotene | |
| ATC code: | L01XF03 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 300 | mg |
| volume of distribution: | 11 | L |
| clearance: | 2.03 | L/h/kg |
| other parameters in model implementation | ||
Bexarotene is a synthetic retinoid, selective agonist of retinoid X receptors (RXRs), used primarily for the treatment of cutaneous T-cell lymphoma (CTCL). It is an FDA-approved therapy for patients with refractory or persistent CTCL.
Pharmacokinetic parameters in adult patients with advanced malignancies and CTCL, both sexes, typical age range 40-75 years.